---
document_datetime: 2025-12-17 23:12:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/aimovig.html
document_name: aimovig.html
version: success
processing_time: 0.1150185
conversion_datetime: 2025-12-28 09:40:33.762364
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Aimovig

[RSS](/en/individual-human-medicine.xml/65541)

##### Authorised

This medicine is authorised for use in the European Union

erenumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Aimovig](#news-on)
- [More information on Aimovig](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month.

Aimovig contains the active substance erenumab.

Expand section

Collapse section

## How is Aimovig used?

Aimovig is injected under the skin using a pre-filled syringe or pen. Patients can inject the medicine themselves after being trained.

The recommended dose is 70 mg every 4 weeks as a single injection. Some patients may benefit from a dose of 140 mg every 4 weeks, given as either a single injection of 140 mg or two injections of 70 mg.

Aimovig can only be obtained with a prescription and treatment should be started by a doctor experienced in the diagnosis and treatment of migraine. For more information about using Aimovig, see the package leaflet or contact your doctor or pharmacist.

## How does Aimovig work?

A chemical messenger called CGRP has been shown to be involved in the development of migraine. The active substance in Aimovig, erenumab, is a monoclonal antibody (a type of protein) designed to attach to a receptor (target) for CGRP on body's cells. By attaching to this receptor, the medicine stops CGRP from attaching to it and causing migraine.

## What benefits of Aimovig have been shown in studies?

Aimovig is effective at reducing the number of days patients suffer migraines. In a study of 667 patients who had migraines 18 days a month on average, those treated with Aimovig had 7 fewer days with migraines per month, compared with 4 fewer days for patients on placebo.

In a second study of 955 patients who had migraines 8 days a month on average, those treated with Aimovig had on average 3 to 4 fewer days with migraines per month compared with around 2 fewer days for patients on placebo.

## What are the risks associated with Aimovig?

The most common side effects with Aimovig (which may affect up to 1 in 10 people) are reactions at the site of injection, constipation, muscle spasms and itching.

For the full list of side effects and restrictions of Aimovig, see the package leaflet.

## Why is Aimovig authorised in the EU?

Aimovig was shown to be effective at reducing the number of days patients have migraines. Only patients with migraines at least 4 days a month were included in the studies as patients with less frequent migraines are not usually eligible for preventative treatment.

Most of the side effects are mild or moderate in severity. The European Medicines Agency therefore decided that Aimovig's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Aimovig?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Aimovig have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Aimovig are continuously monitored. Side effects reported with Aimovig are carefully evaluated and any necessary action taken to protect patients.

## Other information about Aimovig

Aimovig received a marketing authorisation valid throughout the EU on 26 July 2018.

Aimovig : EPAR - Summary for the public

English (EN) (72.56 KB - PDF)

**First published:** 08/08/2018

**Last updated:** 06/05/2019

[View](/en/documents/overview/aimovig-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-5)

български (BG) (98.33 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/bg/documents/overview/aimovig-epar-summary-public_bg.pdf)

español (ES) (72.4 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/es/documents/overview/aimovig-epar-summary-public_es.pdf)

čeština (CS) (95.19 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/cs/documents/overview/aimovig-epar-summary-public_cs.pdf)

dansk (DA) (71.58 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/da/documents/overview/aimovig-epar-summary-public_da.pdf)

Deutsch (DE) (72.84 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/de/documents/overview/aimovig-epar-summary-public_de.pdf)

eesti keel (ET) (71.41 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/et/documents/overview/aimovig-epar-summary-public_et.pdf)

ελληνικά (EL) (103.56 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/el/documents/overview/aimovig-epar-summary-public_el.pdf)

français (FR) (72.93 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/fr/documents/overview/aimovig-epar-summary-public_fr.pdf)

hrvatski (HR) (90.52 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/hr/documents/overview/aimovig-epar-summary-public_hr.pdf)

italiano (IT) (71.76 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/it/documents/overview/aimovig-epar-summary-public_it.pdf)

latviešu valoda (LV) (94.38 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/lv/documents/overview/aimovig-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (94.79 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/lt/documents/overview/aimovig-epar-summary-public_lt.pdf)

magyar (HU) (91.17 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/hu/documents/overview/aimovig-epar-summary-public_hu.pdf)

Malti (MT) (95.48 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/mt/documents/overview/aimovig-epar-summary-public_mt.pdf)

Nederlands (NL) (71.81 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/nl/documents/overview/aimovig-epar-summary-public_nl.pdf)

polski (PL) (96.46 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/pl/documents/overview/aimovig-epar-summary-public_pl.pdf)

português (PT) (72.56 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/pt/documents/overview/aimovig-epar-summary-public_pt.pdf)

română (RO) (93.37 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/ro/documents/overview/aimovig-epar-summary-public_ro.pdf)

slovenčina (SK) (94.77 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/sk/documents/overview/aimovig-epar-summary-public_sk.pdf)

slovenščina (SL) (89.76 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/sl/documents/overview/aimovig-epar-summary-public_sl.pdf)

Suomi (FI) (71.65 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/fi/documents/overview/aimovig-epar-summary-public_fi.pdf)

svenska (SV) (72.18 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/sv/documents/overview/aimovig-epar-summary-public_sv.pdf)

Aimovig : EPAR - Risk management plan

English (EN) (834.86 KB - PDF)

**First published:** 08/08/2018

**Last updated:** 10/12/2025

[View](/en/documents/rmp/aimovig-epar-risk-management-plan_en.pdf)

## Product information

Aimovig : EPAR - Product Information

English (EN) (1007.66 KB - PDF)

**First published:** 08/08/2018

**Last updated:** 01/12/2025

[View](/en/documents/product-information/aimovig-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-259)

български (BG) (1.07 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/bg/documents/product-information/aimovig-epar-product-information_bg.pdf)

español (ES) (1.02 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/es/documents/product-information/aimovig-epar-product-information_es.pdf)

čeština (CS) (1.04 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/cs/documents/product-information/aimovig-epar-product-information_cs.pdf)

dansk (DA) (1.03 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/da/documents/product-information/aimovig-epar-product-information_da.pdf)

Deutsch (DE) (1.1 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/de/documents/product-information/aimovig-epar-product-information_de.pdf)

eesti keel (ET) (1.03 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/et/documents/product-information/aimovig-epar-product-information_et.pdf)

ελληνικά (EL) (1.1 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/el/documents/product-information/aimovig-epar-product-information_el.pdf)

français (FR) (1.04 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/fr/documents/product-information/aimovig-epar-product-information_fr.pdf)

hrvatski (HR) (1023.53 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/hr/documents/product-information/aimovig-epar-product-information_hr.pdf)

íslenska (IS) (1020.33 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/is/documents/product-information/aimovig-epar-product-information_is.pdf)

italiano (IT) (1021.49 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/it/documents/product-information/aimovig-epar-product-information_it.pdf)

latviešu valoda (LV) (1.05 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/lv/documents/product-information/aimovig-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/lt/documents/product-information/aimovig-epar-product-information_lt.pdf)

magyar (HU) (1.09 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/hu/documents/product-information/aimovig-epar-product-information_hu.pdf)

Malti (MT) (1.16 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/mt/documents/product-information/aimovig-epar-product-information_mt.pdf)

Nederlands (NL) (1022.21 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/nl/documents/product-information/aimovig-epar-product-information_nl.pdf)

norsk (NO) (1 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/no/documents/product-information/aimovig-epar-product-information_no.pdf)

polski (PL) (1.07 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/pl/documents/product-information/aimovig-epar-product-information_pl.pdf)

português (PT) (1.06 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/pt/documents/product-information/aimovig-epar-product-information_pt.pdf)

română (RO) (1.1 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/ro/documents/product-information/aimovig-epar-product-information_ro.pdf)

slovenčina (SK) (1.03 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/sk/documents/product-information/aimovig-epar-product-information_sk.pdf)

slovenščina (SL) (1.01 MB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/sl/documents/product-information/aimovig-epar-product-information_sl.pdf)

Suomi (FI) (978.02 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/fi/documents/product-information/aimovig-epar-product-information_fi.pdf)

svenska (SV) (1017.84 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

01/12/2025

[View](/sv/documents/product-information/aimovig-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000309660 01/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Aimovig : EPAR - All Authorised presentations

English (EN) (91.18 KB - PDF)

**First published:** 08/08/2018

**Last updated:** 06/05/2019

[View](/en/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-508)

български (BG) (102.14 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/bg/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.58 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/es/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_es.pdf)

čeština (CS) (50.22 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/cs/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (93.88 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/da/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.67 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/de/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (22.4 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/et/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (49.18 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/el/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_el.pdf)

français (FR) (26.43 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/fr/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (40.25 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/hr/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (22.99 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/is/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_is.pdf)

italiano (IT) (26.23 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/it/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (87.1 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/lv/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (48.41 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/lt/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (99.66 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/hu/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (88.88 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/mt/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (88.53 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/nl/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (92.67 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/no/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_no.pdf)

polski (PL) (47.25 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/pl/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.63 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/pt/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_pt.pdf)

română (RO) (86.06 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/ro/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (45.42 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/sk/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.5 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/sl/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (87.66 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/fi/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.59 KB - PDF)

**First published:**

08/08/2018

**Last updated:**

06/05/2019

[View](/sv/documents/all-authorised-presentations/aimovig-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Aimovig Active substance erenumab International non-proprietary name (INN) or common name erenumab Therapeutic area (MeSH) Migraine Disorders Anatomical therapeutic chemical (ATC) code N02CD01

### Pharmacotherapeutic group

Analgesics

### Therapeutic indication

Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.

## Authorisation details

EMA product number EMEA/H/C/004447 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 01/06/2018 Marketing authorisation issued 26/07/2018 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Aimovig : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (131.46 KB - PDF)

**First published:** 01/12/2025

**Last updated:** 10/12/2025

[View](/en/documents/procedural-steps-after/aimovig-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Aimovig : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (145.14 KB - PDF)

**First published:** 06/05/2019

**Last updated:** 01/12/2025

[View](/en/documents/procedural-steps-after/aimovig-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Aimovig-H-C-PSUSA-00010699-201911 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/392983/2020

English (EN) (130.42 KB - PDF)

**First published:** 09/09/2020

[View](/en/documents/scientific-conclusion/aimovig-h-c-psusa-00010699-201911-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Aimovig-H-C-PSUSA-00010699-201905 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/691366/2019

English (EN) (128.34 KB - PDF)

**First published:** 21/02/2020

[View](/en/documents/scientific-conclusion/aimovig-h-c-psusa-00010699-201905-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Aimovig-H-C-PSUSA-00010699-201811 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/404738/2019

English (EN) (67.78 KB - PDF)

**First published:** 20/09/2019

[View](/en/documents/scientific-conclusion/aimovig-h-c-psusa-00010699-201811-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Aimovig-H-C-4447-X-0001 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/199629/2019

English (EN) (864.75 KB - PDF)

**First published:** 06/05/2019

[View](/en/documents/variation-report/aimovig-h-c-4447-x-0001-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Aimovig : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/413393/2018

English (EN) (2.01 MB - PDF)

**First published:** 08/08/2018

**Last updated:** 08/08/2018

[View](/en/documents/assessment-report/aimovig-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Aimovig

Adopted

Reference Number: EMA/CHMP/283640/2018

English (EN) (68.33 KB - PDF)

**First published:** 01/06/2018

**Last updated:** 01/06/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-aimovig_en.pdf)

#### News on Aimovig

[First monoclonal antibody therapy for prevention of migraine](/en/news/first-monoclonal-antibody-therapy-prevention-migraine) 01/06/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-may-2018) 01/06/2018

#### More information on Aimovig

- [EMEA-001664-PIP02-15-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001664-pip02-15-m06)
- [A non-interventional study to examine patient characteristics and drug utilization patterns in migraine patients treated with prophylactic drugs in Nordic countries - post-authorisation study](https://catalogues.ema.europa.eu/study/50637)
- [Observational Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Erenumab-aooe During Pregnancy (20180172) - post-authorisation study](https://catalogues.ema.europa.eu/study/39424)
- [Specific Drug Use-results Surveillance (Long-term) for Erenumab in Migraine Patients in Japan (20210048) - post-authorisation study](https://catalogues.ema.europa.eu/study/45964)
- [GENESIS: AIMOVIG® Pregnancy Exposure Registry (20180125) - post-authorisation study](https://catalogues.ema.europa.eu/study/39266)
- [Inpatient Constipation Among Migraine Patients Treated With Preventive Medications: A Retrospective Cohort Study in a United States Electronic Health Record Database - post-authorisation study](https://catalogues.ema.europa.eu/study/44534)
- [Risk factors and incidence of inpatient constipation and inpatient constipation with serious complications among migraine patients treated with erenumab: A retrospective cohort study in a US Electronic Health Record Database (20200087) - post-authorisation study](https://catalogues.ema.europa.eu/study/40638)
- [Estimating Event Rates Using the Medication Cohort Module: Hypertension and Negative Control Outcomes in New Users of Onabotulinumtoxin A and Monoclonal Antibodies Targeting the Calcitonin-Gene-Related Pathway in the Marketscan EarlyView Claims Database (20200218) - post-authorisation study](https://catalogues.ema.europa.eu/study/40208)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 10/12/2025

## Share this page

[Back to top](#main-content)